Antisense targeting of 3' end elements involved in DUX4 mRNA processing is an efficient therapeutic strategy for facioscapulohumeral dystrophy: a new gene-silencing approach

Human Molecular Genetics
Anne-Charlotte MarsollierJulie Dumonceaux

Abstract

Defects in mRNA 3'end formation have been described to alter transcription termination, transport of the mRNA from the nucleus to the cytoplasm, stability of the mRNA and translation efficiency. Therefore, inhibition of polyadenylation may lead to gene silencing. Here, we choose facioscapulohumeral dystrophy (FSHD) as a model to determine whether or not targeting key 3' end elements involved in mRNA processing using antisense oligonucleotide drugs can be used as a strategy for gene silencing within a potentially therapeutic context. FSHD is a gain-of-function disease characterized by the aberrant expression of the Double homeobox 4 (DUX4) transcription factor leading to altered pathogenic deregulation of multiple genes in muscles. Here, we demonstrate that targeting either the mRNA polyadenylation signal and/or cleavage site is an efficient strategy to down-regulate DUX4 expression and to decrease the abnormally high-pathological expression of genes downstream of DUX4. We conclude that targeting key functional 3' end elements involved in pre-mRNA to mRNA maturation with antisense drugs can lead to efficient gene silencing and is thus a potentially effective therapeutic strategy for at least FSHD. Moreover, polyadenylation is a ...Continue Reading

References

Dec 1, 1990·Current Opinion in Cell Biology·A Sachs
May 1, 1996·Journal of Medical Genetics·R TuplerL Tiepolo
Jul 19, 2000·Genome Research·E BeaudoingD Gautheret
Mar 10, 2001·Nucleic Acids Research·T A VickersS M Freier
Oct 2, 2002·Nature Genetics·Richard J L F LemmersSilvère M van der Maarel
Jun 26, 2003·Nucleic Acids Research·Michael Zuker
Jan 14, 2005·Nucleic Acids Research·Bin TianCarol S Lutz
Jun 26, 2007·Neuromuscular Disorders : NMD·Valeria KowaljowAlberto L Rosa
Nov 7, 2007·Proceedings of the National Academy of Sciences of the United States of America·Manjusha DixitYi-Wen Chen
Feb 8, 2008·The EMBO Journal·Sven DanckwardtAndreas E Kulozik
Jan 2, 2010·Nucleic Acids Research·Stefania Millevoi, Stéphan Vagner
Mar 27, 2010·The EMBO Journal·Nuno Miguel NunesAndré Furger
Aug 21, 2010·Science·Richard J L F LemmersSilvère M van der Maarel
Nov 10, 2010·PLoS Genetics·Lauren SniderDaniel G Miller
Sep 8, 2011·Genes & Development·Nick J Proudfoot
Nov 5, 2011·PloS One·Céline VanderplanckAlexandra Belayew
Jan 21, 2012·Nature Reviews. Drug Discovery·Ryszard KoleSidney Altman
Apr 18, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·Lindsay M WallaceScott Q Harper
Aug 16, 2012·Current Opinion in Neurology·Silvère M van der MaarelStephen J Tapscott
Oct 31, 2012·Human Molecular Genetics·Hiroaki MitsuhashiLouis M Kunkel
May 21, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Sarah L DeVos, Timothy M Miller
Jun 19, 2013·Nature Reviews. Genetics·Ran ElkonReuven Agami
Jul 4, 2013·Human Molecular Genetics·Gregory J BlockDaniel G Miller
Aug 3, 2013·Annals of Neurology·Jerry R MendellUNKNOWN Eteplirsen Study Group
Aug 24, 2013·Human Molecular Genetics·Maxime FerreboeufJulie Dumonceaux
Nov 19, 2013·Wiley Interdisciplinary Reviews. RNA·Andreas R GruberMihaela Zavolan
Dec 7, 2013·Expert Opinion on Biological Therapy·Susan JarminGeorge Dickson
Jan 11, 2014·EMBO Molecular Medicine·Ina HollererAndreas E Kulozik
Feb 4, 2014·The American Journal of Pathology·Vered RazSilvère M van der Maarel
Mar 5, 2014·Biochemical and Biophysical Research Communications·Hongliang XuYun Yuan
Mar 25, 2014·Human Molecular Genetics·Maxime FerreboeufJulie Dumonceaux

❮ Previous
Next ❯

Citations

Jul 6, 2016·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jennifer Cj ChenKathryn R Wagner
Apr 6, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Valentina SardoneMaria Sofia Falzarano
Jun 22, 2018·Current Treatment Options in Neurology·Ava Y Lin, Leo H Wang
Nov 7, 2017·Muscle & Nerve·Neelam Goyal, Pushpa Narayanaswami
Sep 6, 2018·Cold Spring Harbor Perspectives in Biology·Christine Mayr
Dec 4, 2019·Continuum : Lifelong Learning in Neurology·Kathryn R Wagner
Sep 27, 2019·Nature Reviews. Drug Discovery·Joana DesterroMaria Carmo-Fonseca
Aug 1, 2020·Journal of Personalized Medicine·Eva SidlauskaiteJulie Dumonceaux
Aug 17, 2020·Current Opinion in Neurology·Linde F BouwmanJessica C de Greef
May 13, 2018·International Journal of Molecular Sciences·Anne-Charlotte MarsollierJulie Dumonceaux
Apr 25, 2019·Annual Review of Genomics and Human Genetics·Charis L Himeda, Peter L Jones
Sep 11, 2020·Journal of Clinical Medicine·Laura Le GallJulie Dumonceaux
Jul 9, 2016·Current Opinion in Neurology·Karlien MulBaziel G M van Engelen
Apr 25, 2018·Nature Communications·Evgenia NtiniUlf Andersson Vang Ørom
Mar 18, 2020·Nucleic Acids Research·Lukasz CiszewskiLinda Popplewell
Jul 14, 2020·Medicinal Research Reviews·Epaminondas Doxakis
Jul 1, 2020·Proceedings of the National Academy of Sciences of the United States of America·Kenji Rowel Q LimToshifumi Yokota
Oct 24, 2020·Trends in Molecular Medicine·Justin CohenAngela Lek
Oct 18, 2020·Molecular Therapy : the Journal of the American Society of Gene Therapy·Kenji Rowel Q LimToshifumi Yokota
Nov 12, 2020·Disease Models & Mechanisms·Alec M DeSimoneAngela Lek
Dec 31, 2020·Journal of Personalized Medicine·Romains JoubertJulie Dumonceaux
Jan 30, 2021·Molecular Therapy. Methods & Clinical Development·Charis L HimedaPeter L Jones
Feb 14, 2021·Journal of Neuromuscular Diseases·Leo H Wang, Rabi Tawil
Dec 15, 2020·Molecular Therapy. Nucleic Acids·Virginie MariotJulie Dumonceaux
Mar 30, 2021·Frontiers in Pharmacology·Kenji Rowel Q Lim, Toshifumi Yokota
Apr 18, 2021·Trends in Molecular Medicine·Anna KarpukhinaYegor S Vassetzky

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.